Published in Gene Therapy Weekly, December 26th, 2002
GenStar and Vascular Genetics also announced that they intend to enter into a services agreement for the VEGF-2 product for refractory angina that will be the lead product of the merged company. Separately, GenStar announced financial results for the third quarter of 2002.
The merger between Vascular Genetics and GenStar is expected to be completed during...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly